> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Review Period for Novo Nordisk’s Ozempic
- URL: https://www.fdaweb.com/review-period-for-novo-nordisks-ozempic/
- Published: 2019-12-02T12:00:00.000Z
- Updated: 2026-09-14T15:54:49.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5145622

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Novo Nordisk’s Ozempic (semaglutide), indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus. The regulatory review period is 3,336 days, which includes 2,970 days that occurred during the testing phase and 366 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-11-29/pdf/2019-25850.pdf?ref=fdaweb.com).